On April 18, 2023 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, reported that the Company will host the first in the series of virtual ‘Meet the Expert’ events titled Blocking TGFβ with CRB-601—a New Play for an Old Target, on April 25th at 11:00 AM ET (Press release, Corbus Pharmaceuticals, APR 18, 2023, View Source [SID1234630275]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature Jeffrey Clarke, MD (Duke University School of Medicine) and Joan Seoane, PhD (Vall d’Hebron Institute of Oncology). These distinguished researchers will discuss the challenges and potential opportunities in targeting Transforming Growth Factor β (TGFβ) in oncology. Dr. Clarke is a leading expert in the area of immuno-oncology in the setting of NSCLC, and Dr. Seoane has published extensively on the role of TGFβ in tumor immunosuppression and development of translational tools to guide treatment.
This event will focus on CRB-601, an anti-integrin αvβ8 monoclonal antibody that blocks the activation of latent-TGFβ expressed within the tumor microenvironment. This blockade is designed to reduce local TGFβ levels that are known to promote tumor growth. In non-clinical studies, CRB-601 significantly inhibits tumor growth both as a single agent and in combination with checkpoint inhibition. CRB-601 is scheduled for IND submission in the second half of 2023.
A live Q&A session will follow the formal presentations. To register for the event, please click here.